Your browser doesn't support javascript.
loading
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Wengner, Antje M; Siemeister, Gerhard; Lücking, Ulrich; Lefranc, Julien; Wortmann, Lars; Lienau, Philip; Bader, Benjamin; Bömer, Ulf; Moosmayer, Dieter; Eberspächer, Uwe; Golfier, Sven; Schatz, Christoph A; Baumgart, Simon J; Haendler, Bernard; Lejeune, Pascale; Schlicker, Andreas; von Nussbaum, Franz; Brands, Michael; Ziegelbauer, Karl; Mumberg, Dominik.
Afiliação
  • Wengner AM; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany. antje.wengner@bayer.com.
  • Siemeister G; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Lücking U; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Lefranc J; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Wortmann L; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Lienau P; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Bader B; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Bömer U; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Moosmayer D; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Eberspächer U; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Golfier S; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Schatz CA; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Baumgart SJ; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Haendler B; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Lejeune P; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Schlicker A; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • von Nussbaum F; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Brands M; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Ziegelbauer K; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
  • Mumberg D; Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
Mol Cancer Ther ; 19(1): 26-38, 2020 01.
Article em En | MEDLINE | ID: mdl-31582533
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Métodos Terapêuticos e Terapias MTCI: Terapias_biologicas / Aromoterapia Assunto principal: Dano ao DNA / Proteínas Mutadas de Ataxia Telangiectasia / Neoplasias Idioma: En Revista: Mol Cancer Ther Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Métodos Terapêuticos e Terapias MTCI: Terapias_biologicas / Aromoterapia Assunto principal: Dano ao DNA / Proteínas Mutadas de Ataxia Telangiectasia / Neoplasias Idioma: En Revista: Mol Cancer Ther Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha